• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Local recurrence is an important prognostic factor of hepatocellular carcinoma.局部复发是肝细胞癌的一个重要预后因素。
World J Gastroenterol. 2005 Sep 28;11(36):5601-6. doi: 10.3748/wjg.v11.i36.5601.
2
[Evaluation of prognosis and recurrence of hepatocellular carcinoma treated from 1988 to 2002 at Department of Medicine III, Kyushu University Hospital].[对1988年至2002年在九州大学医院第三内科接受治疗的肝细胞癌患者的预后和复发情况评估]
Fukuoka Igaku Zasshi. 2004 Aug;95(8):195-200.
3
Usefulness of tumor pressure as a prognostic factor in cases of hepatocellular carcinoma where the diameter of the tumor is 3 cm or less.肿瘤压力作为肿瘤直径3厘米及以下的肝细胞癌病例预后因素的有用性。
Cancer. 2002 Aug 1;95(3):596-604. doi: 10.1002/cncr.10690.
4
Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.经导管动脉化疗栓塞术对肝细胞癌术后辅助治疗的临床疗效
World J Surg Oncol. 2016 Apr 2;14:100. doi: 10.1186/s12957-016-0855-z.
5
Standards for selecting percutaneous ethanol injection therapy or percutaneous microwave coagulation therapy for solitary small hepatocellular carcinoma: consideration of local recurrence.孤立性小肝细胞癌经皮乙醇注射治疗或经皮微波凝固治疗的选择标准:对局部复发的考量
Am J Gastroenterol. 1999 Jul;94(7):1914-7. doi: 10.1111/j.1572-0241.1999.01230.x.
6
Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.术后辅助经导管动脉化疗栓塞治疗伴微血管侵犯的肝细胞癌患者的疗效。
World J Gastroenterol. 2017 Nov 7;23(41):7415-7424. doi: 10.3748/wjg.v23.i41.7415.
7
[A new prognostic score system of hepatocellular carcinoma following hepatectomy].[一种肝切除术后肝细胞癌的新预后评分系统]
Zhonghua Zhong Liu Za Zhi. 2017 Dec 23;39(12):903-909. doi: 10.3760/cma.j.issn.0253-3766.2017.12.005.
8
Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.局部三维适形放疗联合经动脉化疗栓塞治疗Ⅲ期肝细胞癌患者的研究
Am J Clin Oncol. 2003 Aug;26(4):e92-9. doi: 10.1097/01.COC.0000077936.97997.AB.
9
Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.经动脉化疗栓塞术难治性肝细胞癌中的肿瘤标志物甲胎蛋白、甲胎蛋白异质体L3和异常凝血酶原
Oncology. 2015;89(3):167-74. doi: 10.1159/000381808. Epub 2015 May 12.
10
Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection.经动脉化疗栓塞后完全坏死可预测根治性切除术后复发性肝内肝细胞癌患者的生存延长。
Ann Surg Oncol. 2010 Mar;17(3):869-77. doi: 10.1245/s10434-009-0788-7. Epub 2009 Dec 22.

引用本文的文献

1
Impact of Thrombocytopenia on Survival in Patients with Hepatocellular Carcinoma: Updated Meta-Analysis and Systematic Review.血小板减少症对肝细胞癌患者生存的影响:更新的荟萃分析和系统评价
Cancers (Basel). 2024 Mar 27;16(7):1293. doi: 10.3390/cancers16071293.
2
Hepatocellular Carcinoma With Different Areas of Right Retroperitoneal Space Invasion: Evaluation of Transcatheter Arterial Chemoembolization Efficacy and Blood Supply Characteristics.伴有右腹膜后间隙不同区域侵犯的肝细胞癌:经动脉化疗栓塞疗效及血供特征评估
Front Oncol. 2020 Sep 23;10:539692. doi: 10.3389/fonc.2020.539692. eCollection 2020.
3
Advantages of Laparoscopic Radiofrequency Ablation Over Percutaneous Radiofrequency Ablation in Hepatocellular Carcinoma.腹腔镜射频消融术相较于经皮射频消融术治疗肝细胞癌的优势
Dig Dis Sci. 2017 Sep;62(9):2586-2600. doi: 10.1007/s10620-017-4688-6. Epub 2017 Jul 25.
4
Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma.肝细胞癌经动脉化疗栓塞术后完全缓解和复发的预测因素
Gut Liver. 2017 May 15;11(3):409-416. doi: 10.5009/gnl16001.
5
The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.血小板计数在肝细胞癌患者中的预后价值:一项系统评价和荟萃分析
Medicine (Baltimore). 2015 Sep;94(37):e1431. doi: 10.1097/MD.0000000000001431.
6
Ethanol injection therapy for small hepatocellular carcinomas located beneath a large vessel using a curved percutaneous ethanol injection therapy needle.使用弯形经皮乙醇注射治疗针治疗位于大血管下方的小肝细胞癌的乙醇注射疗法
Oncol Lett. 2014 Jun;7(6):1831-1834. doi: 10.3892/ol.2014.2053. Epub 2014 Apr 9.
7
The suppressive role and aberrent promoter methylation of BTG3 in the progression of hepatocellular carcinoma.BTG3 在肝细胞癌进展中的抑制作用和异常启动子甲基化。
PLoS One. 2013 Oct 17;8(10):e77473. doi: 10.1371/journal.pone.0077473. eCollection 2013.
8
Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.经动脉化疗栓塞治疗早期肝细胞癌后复发的危险因素。
J Gastroenterol. 2012 Apr;47(4):421-6. doi: 10.1007/s00535-011-0492-9. Epub 2011 Nov 3.
9
Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C.影响丙型肝炎患者联合射频消融和经动脉化疗栓塞治疗后肝癌远处复发的因素。
Cancer Manag Res. 2011;3:267-72. doi: 10.2147/CMR.S22073. Epub 2011 Jul 28.
10
Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature.预处理血清白蛋白作为癌症生存预测指标的系统评价:流行病学文献综述。
Nutr J. 2010 Dec 22;9:69. doi: 10.1186/1475-2891-9-69.

本文引用的文献

1
Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation.射频消融术后肝细胞癌的快速进展
World J Gastroenterol. 2004 Apr 15;10(8):1137-40. doi: 10.3748/wjg.v10.i8.1137.
2
Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma.在对高分化肝细胞癌进行射频消融后出现肉瘤样变的肝细胞癌
Hepatol Res. 2003 Oct;27(2):163-167. doi: 10.1016/s1386-6346(03)00207-9.
3
Combined interventional therapies of hepatocellular carcinoma.肝细胞癌的联合介入治疗
World J Gastroenterol. 2003 Sep;9(9):1885-91. doi: 10.3748/wjg.v9.i9.1885.
4
Prognosis of small hepatocellular carcinoma treated by percutaneous ethanol injection and transcatheter arterial chemoembolization.
J Clin Epidemiol. 2002 Nov;55(11):1095-104. doi: 10.1016/s0895-4356(02)00487-0.
5
Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study.肝切除与经皮乙醇注射治疗小肝细胞癌:一项意大利肝癌研究项目(CLIP 08)回顾性病例对照研究
J Clin Gastroenterol. 2003 Jan;36(1):63-7. doi: 10.1097/00004836-200301000-00017.
6
Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center.与Child B级和C级肝硬化相关的肝细胞癌的治疗预后:单中心411例患者的多因素分析
J Hepatobiliary Pancreat Surg. 2002;9(4):469-77. doi: 10.1007/s005340200058.
7
Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection.
J Gastroenterol Hepatol. 2002 Nov;17(11):1205-10. doi: 10.1046/j.1440-1746.2002.02807.x.
8
Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma.使用顺铂-碘油混悬液经动脉化疗栓塞术与经皮乙醇注射联合治疗晚期小肝细胞癌。
Am J Surg. 2002 Sep;184(3):284-90. doi: 10.1016/s0002-9610(02)00933-9.
9
Clinical short-term results of radiofrequency ablation in liver cancers.肝癌射频消融的临床短期结果
World J Gastroenterol. 2002 Aug;8(4):624-30. doi: 10.3748/wjg.v8.i4.624.
10
Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score.利用CLIP评分预测肝细胞癌患者切除术后的复发及预后
World J Gastroenterol. 2002 Apr;8(2):237-42. doi: 10.3748/wjg.v8.i2.237.

局部复发是肝细胞癌的一个重要预后因素。

Local recurrence is an important prognostic factor of hepatocellular carcinoma.

作者信息

Arimura Eiichirou, Kotoh Kazuhiro, Nakamuta Makoto, Morizono Shusuke, Enjoji Munechika, Nawata Hajime

机构信息

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Fukuoka 812-5282, Japan.

出版信息

World J Gastroenterol. 2005 Sep 28;11(36):5601-6. doi: 10.3748/wjg.v11.i36.5601.

DOI:10.3748/wjg.v11.i36.5601
PMID:16237751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4481474/
Abstract

AIM

To clarify the importance of complete treatment by PEIT.

METHODS

A total of 140 previously untreated cases of HCC were enrolled in this study from 1988 to 2002. The inclusion criteria were: a solitary tumor less than 4 cm in diameter or multiple tumors, fewer than four in number and less than 3 cm in diameter, without extrahepatic metastasis or vessel invasion. As general principles for the treatment of HCC, the patients underwent transcatheter arterial chemoembolization (TACE) prior to PEIT. After the initial treatment of the patients, ultrasonography and computed tomography were performed, and measurement of serum levels of alpha-fetoprotein (AFP) was determined. When tumor recurrences were detected, PEIT and/or TACE were repeated whenever the hepatic functional reserve of the patient permitted. We then analyzed the variables that could influence prognosis, including tumor size and number, the serum levels of AFP, the parameters of hepatic function (albumin, bilirubin, ALT, hepaplastin test, platelet number, and indocyanine green retention at 15 min (ICG-R15)), combined therapy with TACE, distant recurrence, and local recurrence.

RESULTS

Univariate analysis identified the ICG test, serum levels of AFP and albumin, tumor size and number, and local recurrence, but not distant recurrence, as significant prognostic variables. In multivariate analysis using those five parameters, the ICG test, tumor size, tumor number, and local recurrence were identified as significant prognostic factors. In both univariate and multivariate analyses, the relative risk for the ICG test was the highest, followed by local recurrence.

CONCLUSION

We found that local recurrence is an independent prognostic factor of HCC, indicating that achieving complete treatment for HCC on first treatment is important for improving the prognosis of patients with HCC.

摘要

目的

阐明经皮乙醇注射治疗(PEIT)彻底治疗的重要性。

方法

1988年至2002年共有140例未经治疗的肝癌患者纳入本研究。纳入标准为:直径小于4cm的孤立肿瘤或数量少于4个、直径小于3cm的多发肿瘤,无肝外转移或血管侵犯。作为肝癌治疗的一般原则,患者在接受PEIT之前先进行经动脉化疗栓塞术(TACE)。对患者进行初始治疗后,进行超声检查和计算机断层扫描,并测定血清甲胎蛋白(AFP)水平。当检测到肿瘤复发时,只要患者肝功能储备允许,就重复进行PEIT和/或TACE。然后我们分析了可能影响预后的变量,包括肿瘤大小和数量、AFP血清水平、肝功能参数(白蛋白、胆红素、谷丙转氨酶、肝促凝血酶原激酶试验、血小板数量以及15分钟吲哚菁绿潴留率(ICG-R15))、与TACE的联合治疗、远处复发和局部复发。

结果

单因素分析确定吲哚菁绿试验、AFP和白蛋白血清水平、肿瘤大小和数量以及局部复发而非远处复发为显著的预后变量。在使用这五个参数的多因素分析中,吲哚菁绿试验、肿瘤大小、肿瘤数量和局部复发被确定为显著的预后因素。在单因素和多因素分析中,吲哚菁绿试验的相对风险最高,其次是局部复发。

结论

我们发现局部复发是肝癌的一个独立预后因素,这表明首次治疗时对肝癌实现彻底治疗对改善肝癌患者的预后很重要。